<p>Liminatus Pharma Inc. has received notices from the Nasdaq Listing Qualifications Department indicating non-compliance with several Nasdaq listing rules. The company failed to maintain a minimum Market Value of Listed Securities of $50 million and a minimum Market Value of Publicly Held Shares of $15 million over the past 30 consecutive business days. Additionally, Liminatus does not meet requirements for total assets and revenue under another Nasdaq rule. Although these notifications do not immediately affect the company’s stock listing, Liminatus is at risk of delisting if it cannot regain compliance within the prescribed timeframe. The company is actively working to address these deficiencies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-116049), on November 25, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

LIMN

<p>Liminatus Pharma Inc. risks Nasdaq delisting due to non-compliance with listing rules, failing to maintain required market values and asset/revenue criteria. The company is working to address these issues to regain compliance.</p>

Liminatus Pharma Faces Nasdaq Delisting Over Market Value Rule Breach